About US
Contact us
-
Sanofi CEO: Look out below, profits are fallingIt wasn't Sanofi's fourth-quarter profits, which grew by 13%. Nor was it the 8.8% increase in sales for the period, or the 5.3% increase in 2011 sales, to €33.39 billion ($44.3 billion). The headl2012/2/9
-
GSK moves European cash to U.K. nightly 'just in case'GlaxoSmithKline ($GSK) executives like to sleep well at night, not wake up worrying about a banking crisis. So, the company transfers millions of euros every day into U.K. bank accounts to keep cash2012/2/9
-
Sanofi, BMS collect their $444M in Plavix damagesApotex has finally paid its Plavix dues. The generics maker has handed over $444 million to Sanofi ($SNY) and Bristol-Myers Squibb ($BMY), as repayment for its premature launch of generic Plavix bac2012/2/9
-
FDA issues safety alert about PPIs and C. diffThe FDA announced that proton-pump inhibitors used to treat heartburn and acid reflux can increase the risk of diarrhea associated with Clostridium difficile, and said it was working with drugmake2012/2/9
-
Reuters: Nestle leads pack of bidders for Pfizer nutrition unitNestle is the front-runner for Pfizer's nutrition business, Reuters' sources say. The Swiss company is vying with France's Danone for the Pfizer ($PFE) unit, which the drugmaker marked for sale or s2012/2/8
-
Hang on just a bit longer for sales growth, GSK chief saysThings are looking up for GlaxoSmithKline ($GSK)--just not quite yet. We've heard CEO Andrew Witty (photo)talk about "underlying sales growth" for several quarters now, and this earnings announcement2012/2/8
-
Kerry to Expand Center of Excellence with New Cell Science Laboratory Serving Bio-Pharma Customers GloballyNews Release Please contact: Jim Egan 608.363.1200 jim.egan@kerry.com www.kerry.com Kerry to Expand Center of Excellence with New Cell Science Laboratory Serving Bio-Pharma Customers Glob2012/2/8
-
Drugmakers aim to dampen risks in slow-paying countriesAt first, the mere fact that troubled European countries were deep in debt to drugmakers was news. Then, it was the mounting size of those pharma debts and that Greece, at least, was paying its drug2012/2/7
-
Lilly hunkers down for lean years with salary freezeEli Lilly($LLY), languishing in the doldrums of its long-expected "Years YZ," has frozen the salaries of many of its staffers, including those oftop management. As Pharmalot reports, the company dis2012/2/7
-
Medicaid proposal would let states figure base pricesMedicaid drug pricing has long been a complicated, murky area. So murky, in fact, that drugmakers found themselves party to dozens of lawsuits alleging that they'd inflated wholesale prices report2012/2/6